Mark N Levine

Summary

Affiliation: McMaster University
Country: Canada

Publications

  1. doi request reprint Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial
    Alexander G G Turpie
    McMaster University, Hamilton, Ontario L8L 2X2, Canada
    Lancet 373:1673-80. 2009
  2. doi request reprint Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario
    Mark N Levine
    Mark N Levine, Jim A Julian, and Louise Bordeleau, McMaster University, Hamilton Mark N Levine and Louise Bordeleau, Hamilton Health Sciences Juravinski Cancer Centre, Hamilton Mark N Levine and Jim A Julian, Ontario Clinical Oncology Group and Escarpment Cancer Research Institute, Hamilton Philippe L Bedard, Andrea Eisen, Maureen E Trudeau, and Kathleen I Pritchard, University of Toronto, Toronto Phillipe L Bedard, Princess Margaret Hospital, Toronto Andrea Eisen, Maureen E Trudeau, and Kathleen I Pritchard, Odette Sunnybrook Regional Cancer Centre Toronto and Brian Higgins, Peel Regional Cancer Centre, Mississauga, Ontario, Canada
    J Clin Oncol 34:1065-71. 2016
  3. doi request reprint A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer
    M N Levine
    Department of Oncology, McMaster University and Ontario Clinical Oncology Group, Hamilton, Ontario, Canada
    J Thromb Haemost 10:807-14. 2012
  4. ncbi request reprint Adjuvant therapy and thrombosis: how to avoid the problem?
    Mark N Levine
    Department of Oncology, McMaster University, Juravinski Cancer Centre, Hamilton, Ont, Canada
    Breast 16:S169-74. 2007
  5. ncbi request reprint Low-molecular-weight heparin or oral anticoagulation for secondary prevention of deep vein thrombosis in cancer patients
    Mark Levine
    Department of Medicine, Buffett Taylor Chair in Breast Cancer Research, McMaster University, Canada
    Semin Thromb Hemost 29:9-11. 2003
  6. ncbi request reprint Risk assessment and primary VTE prevention in the cancer patient
    Mark N Levine
    McMaster University, Faculty of Health Sciences, Hamilton, Canada
    Pathophysiol Haemost Thromb 33:36-41. 2003
  7. ncbi request reprint Can we optimise treatment of thrombosis?
    Mark N Levine
    Department of Clinical Epidemiology and Biostatistics and Medicine, McMaster University, Room 9, 90 Wing, Main Level, Henderson Hospital, 711 Concession Street, L8V 1C3, Hamilton, ON, Canada
    Cancer Treat Rev 29:19-22. 2003
  8. ncbi request reprint From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer
    M N Levine
    Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
    J Thromb Haemost 1:1456-63. 2003
  9. ncbi request reprint Managing thromboembolic disease in the cancer patient: efficacy and safety of antithrombotic treatment options in patients with cancer
    Mark N Levine
    McMaster University, Hamilton, Ont, Canada L8V IC3
    Cancer Treat Rev 28:145-9. 2002
  10. ncbi request reprint Home-treatment of deep vein thrombosis in patients with cancer
    Mark Levine
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Haematologica 90:150. 2005

Detail Information

Publications78

  1. doi request reprint Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial
    Alexander G G Turpie
    McMaster University, Hamilton, Ontario L8L 2X2, Canada
    Lancet 373:1673-80. 2009
    ..We aimed to test the efficacy and safety of oral rivaroxaban for the prevention of venous thromboembolism after total knee arthroplasty...
  2. doi request reprint Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario
    Mark N Levine
    Mark N Levine, Jim A Julian, and Louise Bordeleau, McMaster University, Hamilton Mark N Levine and Louise Bordeleau, Hamilton Health Sciences Juravinski Cancer Centre, Hamilton Mark N Levine and Jim A Julian, Ontario Clinical Oncology Group and Escarpment Cancer Research Institute, Hamilton Philippe L Bedard, Andrea Eisen, Maureen E Trudeau, and Kathleen I Pritchard, University of Toronto, Toronto Phillipe L Bedard, Princess Margaret Hospital, Toronto Andrea Eisen, Maureen E Trudeau, and Kathleen I Pritchard, Odette Sunnybrook Regional Cancer Centre Toronto and Brian Higgins, Peel Regional Cancer Centre, Mississauga, Ontario, Canada
    J Clin Oncol 34:1065-71. 2016
    ..To evaluate the 21-gene recurrence score (RS) on decision-making in a population-based cohort...
  3. doi request reprint A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer
    M N Levine
    Department of Oncology, McMaster University and Ontario Clinical Oncology Group, Hamilton, Ontario, Canada
    J Thromb Haemost 10:807-14. 2012
    ..Cancer patients receiving chemotherapy are at increased risk for thrombosis. Apixaban, a factor Xa inhibitor, is oral and does not require laboratory monitoring...
  4. ncbi request reprint Adjuvant therapy and thrombosis: how to avoid the problem?
    Mark N Levine
    Department of Oncology, McMaster University, Juravinski Cancer Centre, Hamilton, Ont, Canada
    Breast 16:S169-74. 2007
    ..In the future, new targeted agents may avoid thrombotic complications and a number of new antithrombotic agents which are oral and do not require laboratory monitoring could be used by oncologists to prevent thrombosis...
  5. ncbi request reprint Low-molecular-weight heparin or oral anticoagulation for secondary prevention of deep vein thrombosis in cancer patients
    Mark Levine
    Department of Medicine, Buffett Taylor Chair in Breast Cancer Research, McMaster University, Canada
    Semin Thromb Hemost 29:9-11. 2003
    ....
  6. ncbi request reprint Risk assessment and primary VTE prevention in the cancer patient
    Mark N Levine
    McMaster University, Faculty of Health Sciences, Hamilton, Canada
    Pathophysiol Haemost Thromb 33:36-41. 2003
  7. ncbi request reprint Can we optimise treatment of thrombosis?
    Mark N Levine
    Department of Clinical Epidemiology and Biostatistics and Medicine, McMaster University, Room 9, 90 Wing, Main Level, Henderson Hospital, 711 Concession Street, L8V 1C3, Hamilton, ON, Canada
    Cancer Treat Rev 29:19-22. 2003
    ..0017) in cancer patients without an increase in bleeding...
  8. ncbi request reprint From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer
    M N Levine
    Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
    J Thromb Haemost 1:1456-63. 2003
    ..Finally, the first trial specifically designed to evaluate the anticancer effect of long-term LMWH in cancer patients has been conducted and will no doubt stimulate future research...
  9. ncbi request reprint Managing thromboembolic disease in the cancer patient: efficacy and safety of antithrombotic treatment options in patients with cancer
    Mark N Levine
    McMaster University, Hamilton, Ont, Canada L8V IC3
    Cancer Treat Rev 28:145-9. 2002
    ..However, the use of oral anticoagulants can be problematic in these patients due to possible anorexia and vomiting. The efficacy and safety of long-term treatment of VTE in cancer patients with LMWH is currently under investigation...
  10. ncbi request reprint Home-treatment of deep vein thrombosis in patients with cancer
    Mark Levine
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Haematologica 90:150. 2005
  11. ncbi request reprint Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Tr
    Mark N Levine
    Department of Clinical Epidemiology, McMaster University, Hamilton, Ontario, Canada
    J Clin Oncol 23:5166-70. 2005
    ....
  12. ncbi request reprint Is antithrombotic prophylaxis required in cancer patients with central venous catheters? Still an open question
    M Levine
    Department of CE and B, McMaster University, Hamilton, ON, Canada
    J Thromb Haemost 4:16-8. 2006
  13. doi request reprint New antithrombotic drugs: potential for use in oncology
    Mark N Levine
    Department of Oncology, McMaster University and Juravinski Cancer Centre, Hamilton, Ontario
    J Clin Oncol 27:4912-8. 2009
    ..In this article, the clinical research model used for the development of a new antithrombotic agent is discussed along with the results of recent trials that evaluate these new agents in high-risk populations...
  14. ncbi request reprint Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism
    Agnes Y Y Lee
    Hamilton Health Science, Henderson Hospital, Room 9, 90 Wing, 711 Concession St, Hamilton, ON L8V 1C3, Canada
    J Clin Oncol 23:2123-9. 2005
    ..We investigated the influence of a low molecular weight heparin dalteparin on the survival of patients with active cancer and acute venous thromboembolism...
  15. ncbi request reprint Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer
    Agnes Y Y Lee
    Department of Medicine, McMaster University, Hamilton, Ont, Canada
    N Engl J Med 349:146-53. 2003
    ..We compared the efficacy of a low-molecular-weight heparin with that of an oral anticoagulant agent in preventing recurrent thrombosis in patients with cancer...
  16. doi request reprint Prospective study of 2-[¹⁸F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario clinical oncology group study
    Kathleen I Pritchard
    Ontario Clinical Oncology Group, McMaster University, Hamilton, Canada
    J Clin Oncol 30:1274-9. 2012
    ..2-[(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET) is potentially useful in assessing lymph nodes and detecting distant metastases in women with primary breast cancer...
  17. ncbi request reprint HER2 and responsiveness of breast cancer to adjuvant chemotherapy
    Kathleen I Pritchard
    Toronto Sunnybrook Regional Cancer Centre and the University of Toronto, Toronto, ON, Canada
    N Engl J Med 354:2103-11. 2006
    ....
  18. doi request reprint Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial
    Gail E Darling
    University of Toronto, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada
    J Thorac Oncol 6:1367-72. 2011
    ..If the mediastinum is positive on PET-CT examination, some practitioners conclude that the patient is inoperable and refer the patient for nonsurgical treatment...
  19. pmc The cluster-randomized Quality Initiative in Rectal Cancer trial: evaluating a quality-improvement strategy in surgery
    Marko Simunovic
    Department of Surgery, McMaster University, St Joseph s Healthcare, Hamilton, Ontario, Canada
    CMAJ 182:1301-6. 2010
    ..Following surgery for rectal cancer, two unfortunate outcomes for patients are permanent colostomy and local recurrence of cancer. We tested whether a quality-improvement strategy to change surgical practice would improve these outcomes...
  20. doi request reprint A Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation for Patients With Non-Small-Cell Lung Cancer
    Anand Swaminath
    Department of Oncology, McMaster University, Hamilton, Ontario, Canada Juravinski Cancer Centre, Hamilton Health Sciences, Hamilton, Ontario, Canada Electronic address
    Clin Lung Cancer 17:142-9. 2016
    ..The present trial was designed to examine the efficacy and toxicity of combined erlotinib and palliative chest thoracic RT in non-small-cell lung cancer (NSCLC)...
  21. doi request reprint Randomized trial of decongestive lymphatic therapy for the treatment of lymphedema in women with breast cancer
    Ian S Dayes
    Ian S Dayes, Tim J Whelan, Jim A Julian, Sameer Parpia, and Mark N Levine, McMaster University Tim J Whelan, Jim A Julian, Sameer Parpia, Kathleen I Pritchard, and Mark N Levine, Ontario Clinical Oncology Group Ian S Dayes, Tim J Whelan, and Mark N Levine, Juravinski Cancer Centre Donna Reise, Talspar Nursing Services Jennifer Wiernikowski, Hamilton Health Sciences, Hamilton Kathleen I Pritchard and Lee Manchul, University of Toronto Kathleen I Pritchard, Odette Sunnybrook Cancer Centre Lee Manchul, University Health Network, Toronto David Paul D Souza and Lyn Kligman, London Regional Cancer Program, London David Paul D Souza, University of Western Ontario, London, Ontario Linda LeBlanc, Dr Leon Richard Oncology Centre, Moncton, New Brunswick Margaret L McNeely, University of Alberta and Margaret L McNeely, Cross Cancer Institute, Edmonton, Alberta, Canada
    J Clin Oncol 31:3758-63. 2013
    ..Although massage-based decongestive therapy is often recommended, randomized trials have not consistently demonstrated benefit over more conservative measures...
  22. doi request reprint Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: a phase II randomized study
    Laurie M Elit
    Ontario Clinical Oncology Group OCOG, McMaster University, Hamilton, Canada
    Thromb Res 130:894-900. 2012
    ..A multicentre phase II randomized trial was done to evaluate the antineoplastic potential of dalteparin in ovarian cancer (OC)...
  23. ncbi request reprint Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer
    Agnes Y Y Lee
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    J Clin Oncol 24:1404-8. 2006
    ..We performed a prospective study to examine the incidence, risk factors, and long-term complications of symptomatic catheter-related thrombosis (CRT) in adults with cancer...
  24. doi request reprint Positron Emission Tomography-Computed Tomography (PET-CT) Versus No PET-CT in the Management of Potentially Resectable Colorectal Cancer Liver Metastases: Cost Implications of a Randomized Controlled Trial
    Pablo E Serrano
    McMaster University, Hamilton, Ontario and University of Toronto, Toronto, Ontario, Canada
    J Oncol Pract 12:e765-74. 2016
    ....
  25. pmc Empirical comparison of methods for analyzing multiple time-to-event outcomes in a non-inferiority trial: a breast cancer study
    Sameer Parpia
    Ontario Clinical Oncology Group, Department of Oncology, McMaster University, 711 Concession Street G 60 Wing 1st Floor, Hamilton, ON L8V 1C3, Canada
    BMC Med Res Methodol 13:44. 2013
    ..However, their application to non-inferiority trials is limited. We evaluate four statistical methods for multiple time-to-event endpoints in the context of a non-inferiority trial...
  26. doi request reprint Impact of chemotherapy on thrombin generation and on the protein C pathway in breast cancer patients
    Som D Mukherjee
    Department of Oncology, McMaster University, Hamilton, Ont, Canada
    Pathophysiol Haemost Thromb 37:88-97. 2010
    ..This study suggests that adjuvant chemotherapy in women with breast cancer increases thrombin generation and impairs the endothelium-based protein C anticoagulant pathway...
  27. ncbi request reprint Lymphedema in women with breast cancer: characteristics of patients screened for a randomized trial
    Ian S Dayes
    Department of Oncology, McMaster University, Hamilton, Ontario, Canada
    Breast Cancer Res Treat 110:337-42. 2008
    ..In two centres, patients presenting to lymphedema clinic were screened for eligibility to understand the accrual process and help define the patient population...
  28. pmc Uptake of an innovation in surgery: observations from the cluster-randomized Quality Initiative in Rectal Cancer trial
    Marko Simunovic
    The Department of Surgery, McMaster University, St Joseph s Healthcare, Hamilton, Ont, The Department of Clinical Epidemiology and Biostatistics, Faculty of Health Sciences, McMaster University, Hamilton, Ont, and the Department of Oncology, Faculty of Health Sciences, Juravinski Cancer Centre, Hamilton, Ont
    Can J Surg 56:415-21. 2013
    ..We tested if traditional uptake of innovation concepts applied to surgeons in the experimental arm of the trial...
  29. ncbi request reprint Anti-Xa effect of a low molecular weight heparin (dalteparin) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients
    Michael J Kovacs
    London Health Sciences Centre, 800 Commissioners Road East, London, Ontario, N6A 4G5, Canada
    Thromb Haemost 93:1185-8. 2005
    ..Monitoring of anti-Xa levels in this situation is usually not required...
  30. doi request reprint Prevention of thrombosis in ambulatory patients with cancer
    Punam Rana
    Department of Oncology, McMaster University and Juravinski Cancer Centre, Hamilton, Ontario, Canada
    J Clin Oncol 27:4885-8. 2009
    ..Research is needed to better define a population at high enough risk to warrant pharmacologic prophylaxis and to develop new antithrombotic agents for this indication...
  31. doi request reprint A survivorship care plan for breast cancer survivors: extended results of a randomized clinical trial
    Annelies H Boekhout
    Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada
    J Cancer Surviv 9:683-91. 2015
    ..The 24-month assessments represent the long-term benefit and sustainability of the implantation of a SCP...
  32. pmc Treatment crossovers in time-to-event non-inferiority randomised trials of radiotherapy in patients with breast cancer
    Sameer Parpia
    Ontario Clinical Oncology Group, Department of Oncology, McMaster University, Hamilton, Ontario, Canada
    BMJ Open 4:e006531. 2014
    ..This has led to the use of alternative approaches such as the per-protocol (PP) analysis or the as-treated (AT) analysis, despite the inherent biases of such approaches...
  33. pmc Patterns of use and outcomes for radiation therapy in the Quality Initiative in Rectal Cancer (QIRC) trial
    Valerie Francescutti
    From the Department of Surgery, McMaster University, Hamilton, Ont
    Can J Surg 56:E148-53. 2013
    ..We wished to identify associations between local recurrence risk and use of preoperative, postoperative or no RT...
  34. ncbi request reprint Venous thromboembolism and cancer: risks and outcomes
    Agnes Y Y Lee
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Circulation 107:I17-21. 2003
    ..The antineoplastic effects of anticoagulants are being actively investigated with promising preliminary results...
  35. ncbi request reprint Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia
    James R Wright
    Juravinski Cancer Center at Hamilton Health Sciences, Hamilton, Ontario, Canada
    J Clin Oncol 25:1027-32. 2007
    ..We designed a trial to investigate the effects of epoetin alfa therapy on the QOL of anemic patients with advanced non-small-cell carcinoma of the lung (NSCLC)...
  36. pmc Surgical outcomes in women with ovarian cancer
    Laurie M Elit
    Department of Obstetrics and Gynecology, McMaster University, Hamilton, Ont
    Can J Surg 51:346-54. 2008
    ..We sought to assess whether the specialty of the surgeon or the hospital involved in the initial management of women with ovarian cancer determined the likelihood of unnecessary repeated abdominal surgery and long-term patient survival...
  37. ncbi request reprint Positron emission tomography in staging early lung cancer: a randomized trial
    Donna E Maziak
    Ontario Clinical Oncology Group, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada
    Ann Intern Med 151:221-8, W-48. 2009
    ..Among patients with early-stage non-small cell lung cancer (NSCLC), preoperative imaging tests are important in defining surgical candidates...
  38. doi request reprint Long-term results of hypofractionated radiation therapy for breast cancer
    Timothy J Whelan
    McMaster University and Juravinski Cancer Centre, Hamilton, ON, Canada
    N Engl J Med 362:513-20. 2010
    ..The optimal fractionation schedule for whole-breast irradiation after breast-conserving surgery is unknown...
  39. pmc A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trial
    Melanie Spears
    Transformative Pathology, Ontario Institute for Cancer Research, MaRS Centre, Toronto, ON, Canada
    Oncotarget 7:49099-49106. 2016
    ..06) when treated with EC/T compared to patients treated with CEF.In conclusion we have demonstrated CIN25 and CIN70 as prognostic markers in breast cancer and that CIN4 is a potential predictive maker of benefit from taxane treatment...
  40. pmc The Quality Initiative in Rectal Cancer (QIRC) trial: study protocol of a cluster randomized controlled trial in surgery
    Marko Simunovic
    Department of Surgery, McMaster University, St, Joseph s Healthcare, G838 50 Charlton Ave, East, Hamilton, Ontario, L8N 4A6, Canada
    BMC Surg 8:4. 2008
    ..The strategy is designed to optimize the use of total mesorectal excision techniques...
  41. doi request reprint Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Sam Schulman
    McMaster Clinics, HHS General Hospital, 237 Barton Street E, Hamilton, Ontario, Canada
    Chest 133:257S-298S. 2008
    ..Thrombolytic therapy increases the risk of major bleeding 1.5-fold to threefold in patients with acute venous thromboembolism, ischemic stroke, or ST-elevation myocardial infarction...
  42. ncbi request reprint A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets
    Nancy M Heddle
    Department of Pathology, McMaster University, Hamilton, Ontario, Canada
    Transfusion 42:556-66. 2002
    ..This study evaluates the effectiveness of plasma removal and two methods of prestorage WBC reduction for preventing acute reactions to platelets...
  43. ncbi request reprint Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times
    S S Anand
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Arch Intern Med 159:2029-32. 1999
    ..The presence of an association between early subtherapeutic activated partial thromboplastin times (aPTTs) and recurrent venous thromboembolism (VTE) remains controversial...
  44. ncbi request reprint Cost effectiveness of alternative Helicobacter pylori eradication strategies in the management of duodenal ulcer
    B O'BRIEN
    Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario
    Can J Gastroenterol 11:323-31. 1997
    ..A limitation of the analysis is that it did not incorporate issues of compliance and metronidazole resistance; however, the former concern may be less of an issue as H pylori regimens become simpler and shorter in duration...
  45. ncbi request reprint The place for prescribing guidelines and the means of their dissemination
    M Levine
    Centre for Evaluation of Medicines and McMaster University, Hamilton, Ontario, Canada
    Can J Clin Pharmacol 8:29A-33A. 2001
    ....
  46. ncbi request reprint Pharmacovigilance in a genomic era
    P Farahani
    Centre for Evaluation of Medicines, St Joseph s Hospital, McMaster University, Hamilton, ON, Canada
    Pharmacogenomics J 6:158-61. 2006
  47. ncbi request reprint Epirubicin in breast cancer: present and future
    M Levine
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Clin Breast Cancer 1:S62-7. 2000
    ....
  48. ncbi request reprint Decision-making by healthcare payers
    M Levine
    Centre for Evaluation of Medicines, St Joseph s Healthcare, Hamilton, Ontario, Canada
    Respir Med 96:S31-8. 2002
    ..When data assumptions have to be made, these should be clearly stated with consideration of the impact of varying the assumptions. The impact on budgets should also be considered...
  49. doi request reprint Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy
    Ivo A Olivotto
    Ivo A Olivotto, Tanya Berrang, Pauline T Truong, Alan Nichol, Melanie Reed, and Wayne Beckham, British Columbia Cancer Agency Ivo A Olivotto, Tanya Berrang, and Pauline T Truong, University of British Columbia Wayne Beckham, University of Victoria, Victoria Alan Nichol, University of British Columbia, Vancouver Melanie Reed, University of British Columbia, Kelowna, British Columbia Timothy J Whelan, Do Hoon Kim, Iwa Kong, and Mark N Levine, Juravinski Cancer Centre Timothy J Whelan, Sameer Parpia, Do Hoon Kim, Iwa Kong, Brandy Cochrane, Mark N Levine, and Jim A Julian, McMaster University Timothy J Whelan, Sameer Parpia, Brandy Cochrane, Mark N Levine, and Jim A Julian, Ontario Clinical Oncology Group
    J Clin Oncol 31:4038-45. 2013
    ....
  50. doi request reprint Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial
    Carol anne Moulton
    University Health Network, Toronto, Ontario, Canada
    JAMA 311:1863-9. 2014
    ..Positron emission tomography combined with computed tomography (PET-CT) could help avoid noncurative surgery by identifying patients with occult metastases...
  51. doi request reprint Cost effectiveness of a survivorship care plan for breast cancer survivors
    Doug Coyle
    University of Ottawa Ottawa Hospital Research Institute Applied Health Economics Research Unit, Ottawa Ontario Institute for Cancer Research University of Toronto, Toronto Ontario Clinical Oncology Group McMaster University and Juravinski Regional Cancer Centre, Hamilton, Ontario, Canada
    J Oncol Pract 10:e86-92. 2014
    ....
  52. doi request reprint Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer
    Eva Grunfeld
    Ontario Institute for Cancer Research, Ontario, Canada
    J Clin Oncol 29:4755-62. 2011
    ..An Institute of Medicine report recommends that patients with cancer receive a survivorship care plan (SCP). The trial objective was to determine if an SCP for breast cancer survivors improves patient-reported outcomes...
  53. doi request reprint Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial
    Kathleen I Pritchard
    Sunnybrook Odette Cancer Centre, The University of Toronto, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada
    Breast Cancer Res Treat 131:541-51. 2012
    ..5. An appropriately powered meta-analysis is required to discriminate the predictive value of these three candidate markers...
  54. doi request reprint Funding oncology clinical trials: are cooperative group trials sustainable?
    Hsien Yeang Seow
    McMaster University, Canada
    J Clin Oncol 30:1456-61. 2012
    ..This study investigates whether the payment models used to fund industry versus cooperative group trials contribute to the fiscal deficit of a CTD...
  55. doi request reprint Expectant management versus immediate treatment for low-grade cervical intraepithelial neoplasia : a randomized trial in Canada and Brazil
    Laurie Elit
    Ontario Clinical Oncology Group, Department of Oncology, McMaster University, Hamilton, Ontario, Canada
    Cancer 117:1438-45. 2011
    ..Our objective was to compare the effectiveness of regular colposcopic follow-up and treatment of progressive disease only versus immediate treatment...
  56. ncbi request reprint The importance of reporting patient recruitment details in phase III trials
    James R Wright
    Juravinski Cancer Centre at Hamilton Health Sciences, and Department of Medicine, McMaster University, Hamilton, ON, Canada
    J Clin Oncol 24:843-5. 2006
  57. ncbi request reprint Pilot study of the quality initiative in rectal cancer strategy
    Marko I Simunovic
    Department of Surgery, McMaster University, Hamilton, Ontario, Canada
    Dis Colon Rectum 47:1594-8. 2004
    ..We developed the surgeon-directed, multipronged Quality Initiative in Rectal Cancer strategy to encourage surgeons to use total mesorectal excision techniques...
  58. ncbi request reprint A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes
    B Findlay
    Hotel Dieu Hospital, St Catharines, Ontario, Canada
    Ann Oncol 18:1646-51. 2007
    ..Dose-dense and dose-intensive regimens have improved the outcome of breast cancer in high-risk women with operable disease...
  59. pmc A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trials
    Melanie Spears
    Transformative Pathology, Ontario Institute for Cancer Research, MaRS Centre, Toronto, ON, Canada
    Oncotarget 6:31693-701. 2015
    ..35 (95% CI 0.15-0.80, p = 0.012) for DRFS. This data shows CIN4 is independent predictor of anthracycline benefit for DRFS in breast cancer. ..
  60. pmc Regional Nodal Irradiation in Early-Stage Breast Cancer
    Timothy J Whelan
    From the department of Oncology, McMaster University, and Juravinski Cancer Centre, Hamilton, ON T J W, M N L, Tom Baker Cancer Centre, Calgary, AB I A O, P C, BC Cancer Agency Vancouver Island Centre, Victoria, BC I A O, Queen s University and NCIC Clinical Trials Group, Kingston, ON W R P, Y M, J A W C, B E C, University of Toronto and Sunnybrook Odette Cancer Centre, Toronto I A, K I P, Centre Universitaire de Sherbrooke at Fleurimont Hospital, Sherbrooke, QC A N, Universite de Montreal, Montreal P R, Laval University and L Hôtel Dieu de Québec, Quebec, QC A F, Princess Margaret Hospital, Toronto L M, D R M, Cross Cancer Institute, Edmonton, AB S C, Division of General Internal Medicine and Health Services Research
    N Engl J Med 373:307-16. 2015
    ..Most women with breast cancer who undergo breast-conserving surgery receive whole-breast irradiation. We examined whether the addition of regional nodal irradiation to whole-breast irradiation improved outcomes...
  61. doi request reprint Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study
    Mark J Clemons
    Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa Hospital Research Institute and University of Ottawa, Box 912, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada
    Breast Cancer Res Treat 146:153-62. 2014
    ..04-2.30) and for OS, HR = 2.32 (95 % CI 1.25-4.33). The addition of vandetanib to fulvestrant did not improve biomarker response, PFS or OS in patients with bone metastases. Baseline bone turnover was prognostic for PFS and OS. ..
  62. ncbi request reprint A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer
    Peter J Lovrics
    St Joseph s Healthcare, 50 Charlton Avenue East, Hamilton, Ontario, Canada, L8N 4A6
    Ann Surg Oncol 11:846-53. 2004
    ....
  63. doi request reprint Assessing the volume-outcome hypothesis and region-level quality improvement interventions: pancreas cancer surgery in two Canadian Provinces
    Marko Simunovic
    Department of Surgery, Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada
    Ann Surg Oncol 17:2537-44. 2010
    ..Similar interventions were not used in Quebec, Canada. We assessed the volume-outcome hypothesis and the impact of the Ontario quality improvement interventions...
  64. ncbi request reprint Why cancer patients enter randomized clinical trials: exploring the factors that influence their decision
    James R Wright
    Juravinski Cancer Centre, 699 Concession St, Hamilton, Ontario L8V 5C2
    J Clin Oncol 22:4312-8. 2004
    ..The present study was undertaken to identify the independent predictors of a cancer patient's decision to enter a randomized clinical trial...
  65. pmc A snapshot of waiting times for cancer surgery provided by surgeons affiliated with regional cancer centres in Ontario
    M Simunovic
    Hamilton Regional Cancer Centre, Department of Surgery, Faculty of Health Sciences, McMaster University, Ont
    CMAJ 165:421-5. 2001
    ..INTERPRETATION: Many of the patients with cancer seen by surgeons affiliated with regional cancer centres in Ontario may be experiencing significant delays in the assessment and treatment of their cancer...
  66. ncbi request reprint The 2000 Canadian recommendations for the management of hypertension: part two--diagnosis and assessment of people with high blood pressure
    K B Zarnke
    Department of Medicine, London Health Sciences Centre, University of Western Ontario, 339 Windermere Road, London, Ontario N6A 5A5, Canada
    Can J Cardiol 17:1249-63. 2001
    ..To provide updated, evidence-based recommendations for the diagnosis and assessment of high blood pressure in adults...
  67. pmc Baseline staging tests in primary breast cancer: a practice guideline
    R E Myers
    Department of Oncology, Credit Valley Hospital, Mississauga, Ont
    CMAJ 164:1439-44. 2001
    ....
  68. ncbi request reprint Mastectomy or lumpectomy? Helping women make informed choices
    T Whelan
    Supportive Cancer Care Research Unit and Departments of Medicine, Clinical Epidemiology and Biostatistics, and Surgery, McMaster University, Hamilton, Ontario, Canada
    J Clin Oncol 17:1727-35. 1999
    ..To develop an instrument to help clinicians inform their patients about surgical treatment options for the treatment of breast cancer and to evaluate the impact of the instrument on the clinical encounter...
  69. ncbi request reprint What is the role for antithrombotics in cancer care? Interactive session with panel discussion
    Ajay K Kakkar
    Imperial College, London, UK
    Cancer Treat Rev 28:157-9. 2002
  70. ncbi request reprint neu/erbB-2 overexpression and response to hormonal therapy in premenopausal women in the adjuvant breast cancer setting: will it play in Peoria? part II
    Kathleen I Pritchard
    J Clin Oncol 21:399-400. 2003
  71. ncbi request reprint Adjuvant chemotherapy for breast cancer--30 years later
    Mark N Levine
    N Engl J Med 355:1920-2. 2006
  72. ncbi request reprint Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS)
    Ajay K Kakkar
    Department of Surgical Oncology and Technology, and Cancer Research UK Laboratories, Imperial College, London, United Kingdom
    J Clin Oncol 22:1944-8. 2004
    ..Furthermore, it has been suggested that low molecular weight heparin therapy may prolong survival in patients with cancer. The primary aim of this study was to assess survival at 1 year of patients with advanced cancer...
  73. ncbi request reprint Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    Mark N Levine
    Henderson Research Centre, 711 Concession St, Hamilton, Ontario L8V 1C3
    Chest 126:287S-310S. 2004
    ..In terms of treatment decision making for anticoagulant therapy, bleeding risk cannot be considered alone, ie, the potential decrease in thromboembolism must be balanced against the potential increased bleeding risk...
  74. ncbi request reprint Beyond the development of quality-of-life instruments: where do we go from here?
    Mark N Levine
    J Clin Oncol 20:2215-6. 2002
  75. ncbi request reprint Trastuzumab cardiac side effects: only time will tell
    Mark N Levine
    J Clin Oncol 23:7775-6. 2005
  76. ncbi request reprint Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care
    Eva Grunfeld
    Cancer Outcomes Research Program, Cancer Care Nova Scotia and Dalhousie University, Halifax, Nova Scotia
    J Clin Oncol 24:848-55. 2006
    ..It is usual practice for routine follow-up to take place in specialist clinics. This study tested the hypothesis that follow-up by the patient's family physician is a safe and acceptable alternative to specialist follow-up...
  77. ncbi request reprint American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer
    Gary H Lyman
    Duke University Medical Center, University of Rochester Medical Center, Rochester, USA
    J Clin Oncol 25:5490-505. 2007
    ..To develop guideline recommendations for the use of anticoagulation in the prevention and treatment of venous thromboembolism (VTE) in patients with cancer...
  78. ncbi request reprint Researching the cost of research
    James R Wright
    J Clin Oncol 21:4081-2. 2003